# Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Canonical: https://abierto.us/opportunities/75a50126r00001rfpnpivs27

- Solicitation number: 75A50126R00001_RFP_NPIVS_27
- Notice type: Solicitation
- Status: Open. Offers due November 20, 2026 at 5:00 PM EST
- Department: Department of Health and Human Services
- Agency: Office of Assistant Secretary for Preparedness and Response
- Contracting office: Barda - Aspr / Daappo / Barda DCMA (75A501)
- NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code: AN12 Health R&D Services; Health Care Services; Applied Research
- Place of performance: Washington, District of Columbia
- First posted: August 17, 2026
- Last posted: September 11, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/d547606225884278817f5008d9a07e99/view

## Description

BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods.

Mandatory Qualification Requirements:

To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by:

1. Holding a U.S. influenza vaccine license; or

2. Have developed an influenza vaccine as evidenced by:

                                 a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine

Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.

## Publications

- August 17, 2026: Solicitation, due October 30, 2026 at 5:00 PM EDT. Notice 2e4d29dade93498da98c07dacb2374e6. https://sam.gov/workspace/contract/opp/2e4d29dade93498da98c07dacb2374e6/view
- August 17, 2026: Solicitation, due October 30, 2026 at 5:00 PM EDT. Notice 38ae60ea2cb04f5d8d14713946892925. https://sam.gov/workspace/contract/opp/38ae60ea2cb04f5d8d14713946892925/view
- September 11, 2026: Solicitation, due November 20, 2026 at 5:00 PM EST. Notice d547606225884278817f5008d9a07e99. https://sam.gov/workspace/contract/opp/d547606225884278817f5008d9a07e99/view

## Points of contact

- Laura Saddison, Laura.Saddison@hhs.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75a50126r00001rfpnpivs27.